| abstract |
Provided are heterocyclic compounds of the general formula (I), wherein the variables are as defined in the specification. The preferred compounds are pyridine-carboxamide-piperidine derivatives. Examples of the compounds include N-(4-(4-cyanobenzyl)piperadin-4-yl)-6-(4-(4-fluorobenzyl)piperizine-1-carbonyl)picolinamide; 5-(4-(4-fluorobenzyl)piperazine-1-carbonyl-N-(4-phenylphenyl)picolinamide; 4-((8-(5-(4-(4-fluorobenzyl)piperazine-1-carbonyl)picolinoyl)-2,8-diazaspiro[4.5]decan-2-yl)methyl)benzonitrile; (6-(3-phenylphenylamino)pyridin-3-yl)(4-(4-fluorobenzyl)piperazin-1-yl)methanone; 5-(4-(4-fluorobenzyl)piperazine-1-carbonyl)-N-(4-(4-methylpiperazin-1-yl)phenyl)picolinamide; 5-(4-benzylpiperazine-1-carbonyl)-N-(1-benzylpiperidin-4-yl)picolinamide; pyridine-2,5-diylbis((4-benzylpiperazin-1-yl)methanone) and N-((cis)-3-fluoro-1-(4-(trifluoromethoxy)benzyl)piperidin-4-yl)-6-(4-(4-methoxybenzoyl)piperidine-1-carbonyl)nicotinamide;. The compounds are kinase 5’-AMP-activated protein kinase (AMPK) activators. The compounds may be useful in the treatment or prevention of metabolic disorders such as type II diabetes, atherosclerosis and cardiovascular disease. |